WallStSmart

Guardant Health Inc (GH)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Natera Inc generates 132% more annual revenue ($2.50B vs $1.08B). NTRA leads profitability with a -9.1% profit margin vs -40.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).

GH

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.58

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.8
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GH2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
48.3%10/10

Revenue surging 48.3% year-over-year

Debt/EquityHealth
-9.2610/10

Conservative balance sheet, low leverage

NTRA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
38.8%10/10

Revenue surging 38.8% year-over-year

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Areas to Watch

GH4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-4584.0%2/10

ROE of -4584.0% — below average capital efficiency

Free Cash FlowQuality
$-71.20M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-1.582/10

Distress zone — elevated risk

NTRA4 concerns · Avg: 3.3/10
Price/BookValuation
17.3x4/10

Trading at 17.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-12.8%2/10

ROE of -12.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GH

The strongest argument for GH centers on Revenue Growth, Debt/Equity. Revenue growth of 48.3% demonstrates continued momentum.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.

Bear Case : GH

The primary concerns for GH are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

GH carries more volatility with a beta of 1.62 — expect wider price swings.

GH is growing revenue faster at 48.3% — sustainability is the question.

NTRA generates stronger free cash flow (18M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GH scores higher overall (31/100 vs 31/100) and 48.3% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Guardant Health Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.

Visit Website →

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?